The anti-tumor effect of Alemtuzumab

Alemtuzumab's reduction in circulating B and T cell levels and subsequent regeneration may reduce the likelihood of relapse, ultimately delaying disease progression. Circulating T and B lymphocytes are depleted after each course of treatment. In clinical trials, the lowest cell counts occurred during the first post-treatment blood count after a course of treatment. Lymphocyte counts increase over time: B-cell counts usually recover within 6 months; T-cell counts increase more slowly and often remain below baseline 12 months after treatment. Six months after each course of treatment, about 60% of patients had a total lymphocyte count below the lower limit of normal. After 12 months, 20% of patients had a total lymphocyte count below the lower limit of normal.